BERKELEY HEIGHTS, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced financial results and corporate highlights for the quarter ended March 31, 2017, and recent highlights.
“We began 2017 by successfully building upon the positive momentum of last year,” said Brian A. Leuthner, Edge’s President and Chief Executive Officer. “Our EG-1962 Phase 3 NEWTON 2 study continues to progress in the clinic and we have activated our first site in Europe. We remain on track with our previously stated anticipated timelines for NEWTON 2 top-line efficacy data from the pre-specified interim analysis and from the full study. In addition, we initiated our study assessing EG-1962 administered directly into the basal cisterns of the brain for aneurysmal subarachnoid hemorrhage (aSAH). We also received notification that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has recommended granting a pediatric waiver for EG-1962. On the financial front, we recently added to our strong cash position, which enables us to accelerate timelines for pre-commercial activities for EG-1962 and execute strategies to expand our product portfolio.”
